Safety of ixazomib for the treatment of multiple myeloma

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

(2016) Jacalyn Rosenblatt et al.   BLOOD

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

(2016) S. K. Kumar et al.   BLOOD

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

(2016) Neeraj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

(2016) Neeraj Gupta et al.   BRITISH JOURNAL OF HAEMATOLOGY

Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study

(2016) Neeraj Gupta et al.   INVESTIGATIONAL NEW DRUGS

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

(2016) Neeraj Gupta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The inhibition mechanism of human 20Sproteasomes enables next-generation inhibitor design

(2016) Jil Schrader et al.   SCIENCE

How I treat Langerhans cell histiocytosis

(2015) C. E. Allen et al.   BLOOD

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

(2015) Neeraj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients

(2015) Neeraj Gupta et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Racial/ethnic differences in drug disposition and response: Review of recently approved drugs

(2015) A Ramamoorthy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

(2015) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

(2015) Neeraj Gupta et al.   Journal of Hematology & Oncology

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life

(2015) R. Baz et al.   SUPPORTIVE CARE IN CANCER

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

(2015) S K Kumar et al.   Blood Cancer Journal

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

(2014) S. K. Kumar et al.   BLOOD

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

(2014) P. G. Richardson et al.   BLOOD

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

(2014) A. Garcia-Gomez et al.   CLINICAL CANCER RESEARCH

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

(2014) M. Engelhardt et al.   HAEMATOLOGICA

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

(2014) Shaji K Kumar et al.   LANCET ONCOLOGY

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

(2014) Jesús F San-Miguel et al.   LANCET ONCOLOGY

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

(2013) P. G. Richardson et al.   BLOOD

Primary proteasome inhibition results in cardiac dysfunction

(2013) Joerg Herrmann et al.   EUROPEAN JOURNAL OF HEART FAILURE

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials

(2013) S. Bringhen et al.   HAEMATOLOGICA

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

International Myeloma Working Group recommendations for global myeloma care

(2013) H Ludwig et al.   LEUKEMIA

Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

(2012) P. L. Bergsagel et al.   BLOOD

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

(2012) M. Cavo et al.   BLOOD

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

(2012) A. A. Chanan-Khan et al.   CLINICAL CANCER RESEARCH

The Immunoproteasome as a Target in Hematologic Malignancies

(2012) Deborah J. Kuhn et al.   SEMINARS IN HEMATOLOGY

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

(2011) Dharminder Chauhan et al.   CLINICAL CANCER RESEARCH

When splicing turns bad

(2011) J. Cools   HAEMATOLOGICA

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE